Feeds:
Posts
Comments

Posts Tagged ‘Endo’

I wish all my readers and pharma-industry colleagues a wonderful Thanksgiving holiday!

TODAY’S NEWS

Cephalon, Ception, and CINQUIL: the stats don’t reach significance, but at least all the names are similar – “We are pleased to see a positive biological effect of CINQUIL,” said Steve Tullman, Chief Executive Officer at Ception Therapeutics. “Conducting clinical studies in a new disease area is always challenging. We will continue to review the data from this study and from our ongoing open-label study to find the best path forward for CINQUIL for the treatment of eosinophilic esophagitis.”more

Might a few companies (such as Endo or King) be targets to go private? WSJ reports.

Can pharma sales reps be turned into better value creators? A question we’re all thinking about…

Duh.

Oops. Abbott‘s Meridia weight-loss drug associated with higher rate of cardiovascular events – Meridia is a weight-loss drug approved in 1997. As part of its post-approval commitments, Abbott has been conducting a large study of 10,000 patients to determine whether treatment with Meridia could reduce the number of heart-related adverse events compared to a placebo. In mid-November, however, Abbott reported to regulatory agencies that treatment with Meridia was associated with an 11.4% rate of cardiovascular events compared to 10% for patients treated with placebomore

RECOMMENDED

HR – leadership, compliance, diversity, and more. The Impactiviti network of providers has solutions, not only for pharma sales training, but for a whole range of corporate and HR training (inside and outside of life sciences).  Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.

PLUS

An update on Pfizer’s Social Media initiatives. Encouraging!

JUST FOR FUN

Changing behavior through fun. The Piano Stairs.

———-

Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Read Full Post »

Merck has laid off 750 sales reps so far this year. Ouch.

Genentech to Roche: No. Again (translation: move us from “no” with “dough”…)

Endo brings Indevus into the fold.

PLUS – who is actively involved in social media in pharma? I’m assembling a growing list…here’s what we have so far on this expanding community.

——

Subscribe to the Impactiviti blog via e-mail

Subscribe to the Impactiviti blog via RSS

Connect with Steve Woodruff

Reblog this post [with Zemanta]

Read Full Post »